STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.